Last reviewed · How we verify
Salbutamol (200 µg)
Salbutamol is a short-acting β2 adrenergic receptor agonist that works by stimulating the β2 receptors in the lungs, causing bronchodilation and relaxation of bronchial smooth muscle.
Salbutamol is a short-acting β2 adrenergic receptor agonist that works by stimulating the β2 receptors in the lungs, causing bronchodilation and relaxation of bronchial smooth muscle. Used for Relief of bronchospasm in asthma and COPD, Prevention of bronchospasm during exercise.
At a glance
| Generic name | Salbutamol (200 µg) |
|---|---|
| Sponsor | Novartis |
| Drug class | β2 adrenergic receptor agonist |
| Target | β2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
This leads to an increase in airway diameter, making it easier to breathe. Salbutamol is often used to treat asthma and COPD symptoms by rapidly relieving bronchospasm.
Approved indications
- Relief of bronchospasm in asthma and COPD
- Prevention of bronchospasm during exercise
Common side effects
- Tremors
- Nervousness
- Headache
- Palpitations
Key clinical trials
- A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive (PHASE1)
- Salmeterol Effect on Exercise Performance (NA)
- Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability. (NA)
- Prevalence of Chronic Obstructive Pulmonary Disease in the Portuguese Population
- Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (PHASE4)
- A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects (PHASE4)
- Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF) (NA)
- Clinical Features and Airways Inflammation in Never Smokers and Smokers With COPD
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salbutamol (200 µg) CI brief — competitive landscape report
- Salbutamol (200 µg) updates RSS · CI watch RSS
- Novartis portfolio CI